Literature DB >> 1662632

Azithromycin concentrations in sinus fluid and mucosa after oral administration.

P Karma1, J Pukander, M Penttilä.   

Abstract

The concentrations of azithromycin in sinus fluid and mucosal tissue were determined in a total of 23 patients with acute or chronic sinusitis. Five patients with acute sinusitis and four with chronic sinusitis were administered a five-day course of oral azithromycin (500 mg on day 1, 250 mg on days 2-5, all as single doses), and the remaining 14 patients, all with chronic sinusitis, received single oral doses of azithromycin (500 mg). With the five-day regimen, the mean levels of azithromycin in sinus fluid were markedly higher in patients with acute sinusitis (1.34 micrograms/ml) than in patients with chronic sinusitis (0.25 micrograms/ml) 24 h after the first dose. The levels of azithromycin in the sinus fluid increased from the first to the last dose in both patient groups; the mean levels of azithromycin 24 h after the last dose were 2.33 micrograms/ml in acute sinusitis patients and 0.38 micrograms/ml in chronic sinusitis patients. In chronic sufferers, the mean levels of azithromycin in the sinus fluid following a single oral dose were 0.25, 0.41, 0.57 and 0.22 micrograms/ml at 24, 48, 72 and 96 h, respectively, after administration. In these patients the mean sinus drug concentrations were much greater in the mucosal tissue (1.23 micrograms/g) than in the sinus fluid (0.41 micrograms/ml) 48 h after administration of the single dose. There were no treatment-related changes in laboratory function tests, and side effects were described as mild to moderate (five patients complained of nausea, abdominal pain or headache).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662632     DOI: 10.1007/bf01975841

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.

Authors:  F W Goldstein; M F Emirian; A Coutrot; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Comparison of the acid stability of azithromycin and erythromycin A.

Authors:  E F Fiese; S H Steffen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Pharmacokinetics of azithromycin in rats and dogs.

Authors:  R M Shepard; F C Falkner
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

7.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

8.  Azithromycin concentrations at the sites of pulmonary infection.

Authors:  D R Baldwin; R Wise; J M Andrews; J P Ashby; D Honeybourne
Journal:  Eur Respir J       Date:  1990-09       Impact factor: 16.671

  8 in total
  9 in total

1.  Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area.

Authors:  K C Chern; S K Shrestha; V Cevallos; H L Dhami; P Tiwari; L Chern; J P Whitcher; T M Lietman
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

2.  Examination of high-antibiotic users in a multi-institutional cohort of chronic rhinosinusitis patients.

Authors:  Vijay R Ramakrishnan; Jess C Mace; Zachary M Soler; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2017-01-13       Impact factor: 3.858

3.  Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

Authors:  M H Nguyen; C J Clancy; Y C Yu; A S Lewin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

Review 4.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

5.  Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis.

Authors:  R Hayle; E Lingaas; H O Høivik; T Odegård
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

6.  Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis.

Authors:  Dan C Henry; Ernie Riffer; William N Sokol; Naumann I Chaudry; Robert N Swanson
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 7.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 8.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

9.  Azithromycin and ciprofloxacin inhibit interleukin-8 secretion without disrupting human sinonasal epithelial integrity in vitro.

Authors:  Dong-Jin Lim; Harrison M Thompson; Christopher R Walz; Samrath Ayinala; Daniel Skinner; Shaoyan Zhang; Jessica W Grayson; Do-Yeon Cho; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2020-07-28       Impact factor: 3.858

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.